APA (7th ed.) Citation

McDermott, D. F., Lee, J., Bjarnason, G. A., Larkin, J. M. G., Gafanov, R. A., Kochenderfer, M. D., . . . Atkins, M. B. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of clinical oncology, 39(9), 1020. https://doi.org/10.1200/JCO.20.02363

Chicago Style (17th ed.) Citation

McDermott, David F., et al. "Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma." Journal of Clinical Oncology 39, no. 9 (2021): 1020. https://doi.org/10.1200/JCO.20.02363.

MLA (9th ed.) Citation

McDermott, David F., et al. "Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma." Journal of Clinical Oncology, vol. 39, no. 9, 2021, p. 1020, https://doi.org/10.1200/JCO.20.02363.